Show simple item record

dc.contributor.authorAraujo, Angela M.
dc.contributor.authorAbaurrea, Andrea
dc.contributor.authorAzcoaga, Peio
dc.contributor.authorLópez Velazco, Joanna I.
dc.contributor.authorManzano, Sara
dc.contributor.authorRodríguez Martínez, Javier
dc.contributor.authorRezola, Ricardo
dc.contributor.authorEgia Mendikute, Leire
dc.contributor.authorValdés Mora, Fátima
dc.contributor.authorFlores, Juana M.
dc.contributor.authorJenkins, Liam
dc.contributor.authorPulido, Laura
dc.contributor.authorOsorio Querejeta, Iñaki
dc.contributor.authorFernández Nogueira, Patricia
dc.contributor.authorFerrari, Nicola
dc.contributor.authorViera, Cristina
dc.contributor.authorMartín Martín, Natalia
dc.contributor.authorTzankov, Alexandar
dc.contributor.authorEppenberger Castori, Serenella
dc.contributor.authorÁlvarez López, Isabel
dc.contributor.authorUrruticoechea, Ander
dc.contributor.authorBragado, Paloma
dc.contributor.authorColeman, Nicholas
dc.contributor.authorPalazón, Asís
dc.contributor.authorCarracedo Pérez, Arkaitz ORCID
dc.contributor.authorGallego Ortega, David
dc.contributor.authorCalvo González, Fernando
dc.contributor.authorIsacke, Clare M.
dc.contributor.authorCaffarel, María M.
dc.contributor.authorLawrie, Charles
dc.date.accessioned2022-04-20T10:25:59Z
dc.date.available2022-04-20T10:25:59Z
dc.date.issued2022-04-01
dc.identifier.citationJournal of Clinical Investigation 132(7) : (2022) // Article ID e148667es_ES
dc.identifier.issn1558-8238
dc.identifier.urihttp://hdl.handle.net/10810/56368
dc.description.abstract[EN] The tumor microenvironment (TME) is reprogrammed by cancer cells and participates in all stages of tumor progression. The contribution of stromal cells to the reprogramming of the TME is not well understood. Here, we provide evidence of the role of the cytokine oncostatin M (OSM) as central node for multicellular interactions between immune and nonimmune stromal cells and the epithelial cancer cell compartment. OSM receptor (OSMR) deletion in a multistage breast cancer model halted tumor progression. We ascribed causality to the stromal function of the OSM axis by demonstrating reduced tumor burden of syngeneic tumors implanted in mice lacking OSMR. Single-cell and bioinformatic analysis of murine and human breast tumors revealed that OSM expression was restricted to myeloid cells, whereas OSMR was detected predominantly in fibroblasts and, to a lower extent, cancer cells. Myeloid-derived OSM reprogrammed fibroblasts to a more contractile and tumorigenic phenotype and elicited the secretion of VEGF and proinflammatory chemokines CXCL1 and CXCL16, leading to increased myeloid cell recruitment. Collectively, our data support the notion that the stromal OSM/OSMR axis reprograms the immune and nonimmune microenvironment and plays a key role in breast cancer progression.es_ES
dc.description.sponsorshipThis work was funded by Spanish Ministry of Science and Innovation - ISCIII (PI15/00623, PI18/00458, PI21/01208, CP18/00076, and FI19/00193); European Regional Development (FEDER) funds; Basque Department of Health (2017111011); Fundación SEOM (Beca SEOM-Font Vella); Fundación Gangoiti; and Ikerbasque Basque Research Foundation. The group also received funds from the breast cancer patient’s charity Katxalin and from Roche Farma S.A. AMA and AA are funded by Basque Government Doctoral Training Grants. JILV is funded by an AECC PhD Fellowship. FVM is supported by the Career Development Fellowship from the Cancer Institute New South Wales (2019/CDF002). AP’s research is funded by the European Research Council (ERC, ERC-2018-StG 804236-NEXTGEN-IO), and by the Spanish Ministry of Science and Innovation (PID2019-107956RA-I00 and RYC2018-024183-I). AC’s research is supported by the Basque Department of Industry, Tourism and Trade (Elkartek); the MICINN (PID2019-108787RB-I00 [FEDER/EU]; Excellence Network (SAF2016-81975-REDT); European Training Networks Project (H2020-MSCA-ITN-308 2016 721532); the AECC (GCTRA18006CARR), Vencer el Cáncer Foundation; La Caixa Foundation (ID 100010434), under the agreement LCF/PR/HR17/; and the ERC (Consolidator Grant 819242). CIBERONC was cofunded with FEDER funds and funded by ISCIII. DGO is supported by a Cancer Council NSW project grant (RG18-03) and the National Breast Cancer Foundation Elaine Henry Fellowship (IIRS-21-096). FC is funded by Institute of Cancer Research, Spanish Ministry of Science and Innovation (RYC-2016-20352 and RTI2018-096778-A-I00); Asociacion Española Contra el Cancer (LAB-AECC, LABAE19044CALV); and BBVA Leonardo Awards (IN[19]_BBM_BAS_0076).es_ES
dc.language.isoenges_ES
dc.publisherAmerican Society of Clinical Investigationes_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/804236es_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/721532es_ES
dc.relationinfo:eu-repo/grantAgreement/MINECO/RYC-2016-20352es_ES
dc.relationinfo:eu-repo/grantAgreement/MICIU/RYC2018-024183-Ies_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2019-107956RA-I00es_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2019-108787RB-I00es_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/819242es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectbreast canceres_ES
dc.subjectchemokineses_ES
dc.subjectcytokineses_ES
dc.subjectinflammationes_ES
dc.subjectoncologyes_ES
dc.titleStromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironmentes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© 2022 Araujo et al. This work is licensed under the Creative Commons Attribution 4.0 International license. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.jci.org/articles/view/148667es_ES
dc.identifier.doi10.1172/JCI148667
dc.contributor.funderEuropean Commission
dc.departamentoesBioquímica y biología moleculares_ES
dc.departamentoeuBiokimika eta biologia molekularraes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 Araujo et al. This work is licensed under the Creative Commons Attribution 4.0 International license. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as © 2022 Araujo et al. This work is licensed under the Creative Commons Attribution 4.0 International license. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/